Odyssey Therapeutics announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets. The companies will combine their expertise in artificial intelligence, machine learning, computational chemistry and drug discovery to unlock difficult-to-drug targets. The agreement was facilitated by Johnson & Johnson Innovation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Paging Dr. Nvidia (NASDAQ:NVDA): AI and Healthcare
- J&J to pay $75M to settle $6B baby powder lawsuit, Bloomberg reports
- J&J to pay $75M to settle Mississipi talc lawsuit, Bloomberg says
- Judge gives J&J new chance to contest evidence on talc products, Reuters says
- Piper says competitive process could materialize for ShockWave
